Metastatic Medullary Thyroid Cancer clinical trials

Explore recruiting metastatic medullary thyroid cancer clinical trials.

Recruiting metastatic medullary thyroid cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Medullary Thyroid Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Hungary, Poland, Romania, Croatia

Therapeutic use (Phase IV) EU CTIS Study details

Metastatic Medullary Thyroid Cancer trials by city

Metastatic Medullary Thyroid Cancer clinical trials

Recruiting metastatic medullary thyroid cancer studies right now

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Also recruiting in Europe

A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Metastatic Medullary Thyroid Cancer trials by city

Other conditions